APA (7th ed.) Citation

Cai, H., Chen, S., Tang, S., Xiao, Y., Shi, F., Wu, Z., . . . Guo, W. Lenvatinib and tislelizumab versus atezolizumab and bevacizumab in combination with TAE-HAIC for unresectable hepatocellular carcinoma with high tumor burden: A multicenter retrospective cohort study. Springer.

Chicago Style (17th ed.) Citation

Cai, Hongjie, et al. Lenvatinib and Tislelizumab Versus Atezolizumab and Bevacizumab in Combination with TAE-HAIC for Unresectable Hepatocellular Carcinoma with High Tumor Burden: A Multicenter Retrospective Cohort Study. Springer.

MLA (9th ed.) Citation

Cai, Hongjie, et al. Lenvatinib and Tislelizumab Versus Atezolizumab and Bevacizumab in Combination with TAE-HAIC for Unresectable Hepatocellular Carcinoma with High Tumor Burden: A Multicenter Retrospective Cohort Study. Springer.